Ionis Pharmaceuticals gets grant for modified oligonucleotide for reducing lRRK2 rna in neurodegenerative diseases
Discover how Ionis Pharmaceuticals' patent for modified oligonucleotides offers hope in treating Parkinson's disease by reducing LRRK2 levels and alleviating symptoms. Explore the groundbreaking methods and compounds outlined in this comprehensive framework.
Discover how Ionis Pharmaceuticals' patent for modified oligonucleotides offers hope in treating Parkinson's disease by reducing LRRK2 levels and alleviating symptoms. Explore the groundbreaking methods and compounds outlined in this comprehensive framework.
What's Your Reaction?
